Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AGN016
MIFTS: 63

Aging

Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Aging

About this section

MalaCards integrated aliases for Aging:

Name: Aging 58 77 3

External Ids:

OMIM 58 502000
Sources

Summaries for Aging

About this section
OMIM : 58 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000)

MalaCards based summary : Aging is related to age-related hearing loss and huntington disease. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Cellular Senescence (REACTOME). The drugs Acetylcholine and Metformin have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Senescence (/sɪˈnɛsəns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Sources

Related Diseases for Aging

About this section

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 4199)
# Related Disease Score Top Affiliating Genes
1 age-related hearing loss 33.6 HIF1A SOD2
2 huntington disease 32.1 AKT1 PPARG SNCA SOD1 TP53
3 atypical werner syndrome 31.9 LMNA WRN
4 prostate disease 31.7 AKT1 PPARG TP53
5 vascular disease 31.7 MAPK1 NAMPT PPARG SERPINE1 SOD1
6 leukemia, acute myeloid 31.5 AKT1 JUN PARP1 SNCA TP53
7 breast disease 31.4 PARP1 PPARG SOD2 TP53
8 prostate cancer 31.1 AKT1 HIF1A JUN MAPK1 PARP1 PDGFRB
9 esophageal cancer 30.9 AKT1 BCYRN1 HIF1A JUN TP53
10 ovarian cancer 30.7 AKT1 BCYRN1 HIF1A JUN MAPK1 PARP1
11 diabetes mellitus 30.7 AKT1 MAPK1 NAMPT PPARG SERPINE1 SOD2
12 body mass index quantitative trait locus 11 30.5 AKT1 LMNA NAMPT PPARG SERPINE1
13 colorectal cancer 30.4 AKT1 BCYRN1 HIF1A JUN MAPK1 PARP1
14 endometrial cancer 30.2 AKT1 HIF1A JUN MAPK1 TP53
15 overnutrition 30.1 NAMPT PPARG SERPINE1
16 glioblastoma multiforme 30.0 AKT1 HIF1A MAPK1 PDGFRB PPARG TP53
17 nasopharyngeal carcinoma 30.0 AKT1 HIF1A JUN PARP1 TP53
18 endometrial adenocarcinoma 29.9 AKT1 HIF1A TP53
19 breast adenocarcinoma 29.8 AKT1 MAPK1 PARP1 TP53
20 nervous system disease 29.6 AKT1 SNCA SOD1 TP53
21 ewing sarcoma 29.5 AKT1 HIF1A JUN MAPK1 PARP1 PDGFRB
22 glucose metabolism disease 29.5 AKT1 PPARG SERPINE1
23 squamous cell carcinoma 29.5 AKT1 BCYRN1 MAPK1 TP53 TP63
24 cervical cancer 29.4 AKT1 BCYRN1 HIF1A PARP1 TP53 TP63
25 glioblastoma 29.4 AKT1 BCYRN1 HIF1A MAPK1 PDGFRB PPARG
26 large intestine cancer 29.4 AKT1 HIF1A JUN PARP1 PPARG TP53
27 squamous cell carcinoma, head and neck 29.3 AKT1 HIF1A TP53 TP63
28 endocrine gland cancer 29.1 AKT1 PARP1 TP53
29 lung cancer susceptibility 3 29.1 AKT1 HIF1A JUN MAPK1 PARP1 TP53
30 marek disease 29.1 JUN TP53
31 lung cancer 29.0 AKT1 BCYRN1 HIF1A JUN MAPK1 PARP1
32 macular degeneration, age-related, 1 12.6
33 neuropathy, hereditary, with or without age-related macular degeneration 12.4
34 macular degeneration, age-related, 13 12.4
35 macular degeneration, age-related, 2 12.4
36 macular degeneration, age-related, 5 12.4
37 macular degeneration, age-related, 9 12.4
38 macular degeneration, age-related, 7 12.4
39 macular degeneration, age-related, 8 12.4
40 macular degeneration, age-related, 4 12.4
41 macular degeneration, age-related, 12 12.4
42 macular degeneration, age-related, 14 12.4
43 macular degeneration, age-related, 11 12.4
44 macular degeneration, age-related, 6 12.4
45 macular degeneration, age-related, 15 12.4
46 macular degeneration, age-related, 10 12.4
47 premature aging syndrome, penttinen type 12.4
48 age-related hearing impairment 1 12.2
49 age-related hearing impairment 2 12.2
50 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 12.1

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging
Sources

Symptoms & Phenotypes for Aging

About this section

Clinical features from OMIM:

502000

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.63 MAPK1
2 Decreased viability GR00221-A-1 10.63 AKT1 MAPK1 PDGFRB PPARG
3 Decreased viability GR00221-A-2 10.63 AKT1 PPARG SOD1 JUN
4 Decreased viability GR00221-A-3 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1 JUN
5 Decreased viability GR00221-A-4 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1
6 Decreased viability GR00231-A 10.63 MAPK1
7 Decreased viability GR00342-S-1 10.63 MAPK1 PDGFRB
8 Decreased viability GR00342-S-2 10.63 MAPK1
9 Decreased viability GR00342-S-3 10.63 MAPK1
10 Decreased viability GR00402-S-2 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1 JUN
11 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 HIF1A JUN PARP1 SOD1 TP53 TP63
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 AKT1 HIF1A JUN SNCA SOD1 TP53
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 AKT1 HIF1A JUN MAPK1 SNCA SOD1

MGI Mouse Phenotypes related to Aging:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 AKT1 HIF1A JUN KL LMNA MAPK1
2 growth/size/body region MP:0005378 10.54 AKT1 HIF1A JUN KL LMNA MAPK1
3 cellular MP:0005384 10.52 AKT1 HIF1A JUN KL LMNA MAPK1
4 homeostasis/metabolism MP:0005376 10.51 AKT1 HIF1A JUN KL LMNA MAPK1
5 behavior/neurological MP:0005386 10.5 AKT1 HIF1A JUN KL LMNA MAPK1
6 immune system MP:0005387 10.5 AKT1 HIF1A JUN KL LMNA MAPK1
7 integument MP:0010771 10.47 AKT1 HIF1A JUN KL LMNA MAPK1
8 mortality/aging MP:0010768 10.45 AKT1 HIF1A JUN KL LMNA MAPK1
9 endocrine/exocrine gland MP:0005379 10.44 AKT1 HIF1A JUN KL LMNA MAPK1
10 hematopoietic system MP:0005397 10.44 AKT1 HIF1A JUN KL LMNA MAPK1
11 adipose tissue MP:0005375 10.33 AKT1 KL LMNA PDGFRB PPARG SERPINE1
12 embryo MP:0005380 10.3 AKT1 HIF1A JUN MAPK1 NAMPT PARP1
13 liver/biliary system MP:0005370 10.29 AKT1 HIF1A JUN KL LMNA MAPK1
14 nervous system MP:0003631 10.28 AKT1 HIF1A JUN KL LMNA MAPK1
15 digestive/alimentary MP:0005381 10.26 HIF1A KL LMNA MAPK1 PDGFRB SNCA
16 muscle MP:0005369 10.22 AKT1 HIF1A KL LMNA MAPK1 PDGFRB
17 craniofacial MP:0005382 10.21 HIF1A KL LMNA MAPK1 PDGFRB TP53
18 hearing/vestibular/ear MP:0005377 10.18 KL LMNA MAPK1 PARP1 PPARG SOD1
19 neoplasm MP:0002006 10.16 AKT1 HIF1A MAPK1 PPARG SERPINE1 SOD1
20 limbs/digits/tail MP:0005371 10.07 HIF1A KL LMNA PDGFRB TP53 TP63
21 normal MP:0002873 10.07 AKT1 HIF1A JUN LMNA PDGFRB PPARG
22 reproductive system MP:0005389 10.07 AKT1 KL LMNA MAPK1 PARP1 PDGFRB
23 renal/urinary system MP:0005367 10.06 HIF1A KL LMNA PARP1 PDGFRB PPARG
24 no phenotypic analysis MP:0003012 9.95 JUN PARP1 PPARG SIRT3 SNCA TP53
25 respiratory system MP:0005388 9.81 AKT1 HIF1A JUN KL LMNA MAPK1
26 skeleton MP:0005390 9.77 AKT1 HIF1A JUN KL LMNA MAPK1
27 vision/eye MP:0005391 9.44 HIF1A JUN KL LMNA MAPK1 PARP1
Sources

Drugs & Therapeutics for Aging

About this section

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 953)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
4
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 5311068 68602
6
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
7
Digoxin Approved Phase 4 20830-75-5 2724385 30322
8
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9002-64-6
9
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
10
Pantoprazole Approved Phase 4 102625-70-7 4679
11
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
12
Rilpivirine Approved Phase 4 500287-72-9
13
Darunavir Approved Phase 4,Phase 2 206361-99-1, 635728-49-3 213039
14
Cobicistat Approved Phase 4 1004316-88-4
15
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 71-58-9
17
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
18
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0, 481-30-1 10204 6013
19
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
20
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
21
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
22
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
23
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
24 Orange Approved Phase 4,Phase 3,Not Applicable
25 Grape Approved Phase 4,Phase 2,Phase 1,Not Applicable
26
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
27
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 137-58-6 3676
28
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
29
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
30
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
33
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 124-94-7 31307
34
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
35
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
36
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
37
Naproxen Approved, Vet_approved Phase 4,Phase 2,Phase 3 22204-53-1 156391 1302
38
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
39
Lithium carbonate Approved Phase 4,Phase 2 554-13-2
40
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
41
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 28014-46-2
42
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
43
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
44
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 69-65-8 6251 453
45
Emtricitabine Approved, Investigational Phase 4,Phase 2 143491-57-0 60877
46
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 2 147127-20-6 464205
47
Atorvastatin Approved Phase 4,Phase 3,Phase 2 134523-00-5 60823
48
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
49
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
50
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687

Interventional clinical trials:

(show top 50) (show all 3806)
# Name Status NCT ID Phase Drugs
1 Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
2 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
3 Metformin Induces a Dietary Restriction-like State in Human Unknown status NCT02745886 Phase 4 metformin 0.85 twice daily for 6 months
4 Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
5 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
6 Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
7 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
8 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
9 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
10 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
11 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
12 Frailty and Cognitive Function Assessment of TAVI Patients Unknown status NCT02650388 Phase 4
13 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
14 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
15 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
16 The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population Unknown status NCT00966199 Phase 4 anti-hypertensive medication
17 Herbal Alternatives for Menopause Symptoms (HALT Study) Unknown status NCT00169299 Phase 4 Black cohosh;Multibotanical preparation;Multibotanical preparation + dietary soy counseling;Conjugated equine estrogen +/- medroxyprogesterone acetate
18 A Dose Finding Study for Pain Relief of a Broken Hip Unknown status NCT00926666 Phase 4 Levobupivacaine
19 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
20 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
21 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
22 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
23 Retinol on Human Skin Aging in East Asian Descent Completed NCT02906566 Phase 4 Retinol;Placebo
24 Volume Restoration of the Aging Midface With Sculptra Aesthetic Completed NCT01307865 Phase 4 injectable poly-L-lactic acid
25 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces Completed NCT02312154 Phase 4
26 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen Completed NCT02577042 Phase 4 Raltegravir;PI-based regimen;Atorvastatin
27 Pectin, Aging and Intestinal Barrier Function Completed NCT02376270 Phase 4
28 Brain Imaging and Mental Disorders of Aging Intervention Completed NCT00267163 Phase 4 donepezil;Placebo
29 PPV: Pneumococcal Polysaccharide Vaccine in Older Adults Completed NCT00239694 Phase 4
30 Canadian Aesthetic Experience With Sculptra Therapy Completed NCT00447551 Phase 4 Poly-L-Lactic Acid
31 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
32 Aging Brain Changes, Executive Dysfunction and Depression Completed NCT00918684 Phase 4 Escitalopram
33 Memory and Mental Health in Aging Completed NCT02988908 Phase 4 Donepezil;Placebos
34 Testosterone Effects on Bone and Frailty Completed NCT00182871 Phase 4 testosterone
35 Brain Aging and Treatment Response in Geriatric Depression Completed NCT01902004 Phase 4 Escitalopram;Memantine;Placebo
36 The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET) Completed NCT01016210 Phase 4 Leuveris;Leuveris
37 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
38 Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance Completed NCT01740440 Phase 4
39 Comparative Study of the Effect of Dysport and Botox Completed NCT00434863 Phase 4 botulinum toxin type A
40 Poly-L-lactic Acid for Skin Quality Completed NCT02003833 Phase 4
41 Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women Completed NCT01598272 Phase 4
42 Comparison of Outcome Parameters in Laser Rhytide Treatment Completed NCT00994474 Phase 4
43 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines Completed NCT00856414 Phase 4
44 Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles Completed NCT01212809 Phase 4
45 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
46 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
47 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4 simvastatin;pravastatin
48 Optimizing Body Composition for Function in Older Adults Completed NCT00315146 Phase 4 Pioglitazone;Placebo
49 Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women Completed NCT00352157 Phase 4
50 Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study Completed NCT01529788 Phase 4 Right lateral orbital injection of Botox Cosmetic or Dysport;Left lateral orbital injection of Botox Cosmetic or Dysport

Search NIH Clinical Center for Aging

Sources

Genetic Tests for Aging

About this section
Sources

Anatomical Context for Aging

About this section

MalaCards organs/tissues related to Aging:

42
Brain, Skin, Bone, Heart, Breast, Kidney, Testes
Sources

Publications for Aging

About this section

Articles related to Aging:

(show top 50) (show all 7417)
# Title Authors Year
1
About "Anti-aging effects of ingenol mebutate for patients with actinic keratosis" and phenol-croton oil peelings. ( 30716406 )
2019
2
Aging and Comorbidities in Acute Pancreatitis I: A Meta-Analysis and Systematic Review Based on 194,702 Patients. ( 31001131 )
2019
3
Physical Activity, Injurious Falls, and Physical Function in Aging: An Umbrella Review. ( 31095087 )
2019
4
The impact of aging on neurophysiological entrainment to a metronome. ( 31095111 )
2019
5
Cellular labeling of endogenous retrovirus replication (CLEVR) reveals de novo insertions of the gypsy retrotransposable element in cell culture and in both neurons and glial cells of aging fruit flies. ( 31095565 )
2019
6
Healthy aging affects cerebrovascular reactivity and pressure-flow responses, but not neurovascular coupling: A cross-sectional study. ( 31095646 )
2019
7
Objectively measured sedentary time before and after transition to retirement:The Finnish Retirement and Aging Study (FIREA). ( 31095675 )
2019
8
Assessing blood pressure and arterial aging in pharmacies-New hope for blood pressure control in the community? ( 31095850 )
2019
9
Measurement of arterial stiffness and vascular aging in community pharmacies-The ASINPHAR@2action project. ( 31095865 )
2019
10
Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. ( 31095969 )
2019
11
The Association between Green and Black Tea Consumption on Successful Aging: A Combined Analysis of the ATTICA and MEDiterranean ISlands (MEDIS) Epidemiological Studies. ( 31096548 )
2019
12
Newly Generated and Non-Newly Generated "Immature" Neurons in the Mammalian Brain: A Possible Reservoir of Young Cells to Prevent Brain Aging and Disease? ( 31096632 )
2019
13
The Effect of Exercise on Glucoregulatory Hormones: A Countermeasure to Human Aging: Insights from a Comprehensive Review of the Literature. ( 31096708 )
2019
14
Cataractogenic load - A concept to study the contribution of ionizing radiation to accelerated aging in the eye lens. ( 31097153 )
2019
15
Evaluating attitudes about aging and body comparison as moderators of the relationship between menopausal status and disordered eating and body image concerns among middle-aged women. ( 31097174 )
2019
16
Understanding Aging in Bipolar Disorder by Integrating Archival Clinical Research Datasets. ( 31097301 )
2019
17
Residual monomer elution from different conventional and CAD/CAM dental polymers during artificial aging. ( 31098712 )
2019
18
Aging renders desynchronization between clock and immune genes in male Wistar rat kidney: chronobiotic role of curcumin. ( 31098769 )
2019
19
Moderating effects of age on relationships between attitudes to aging and well-being outcomes. ( 31099260 )
2019
20
Adhesion behavior of conventional and high-translucent zirconia: Effect of surface conditioning methods and aging using an experimental methodology. ( 31099974 )
2019
21
Immune Correlates of Diffuse Myocardial Fibrosis and Diastolic Dysfunction Among Aging Women With Human Immunodeficiency Virus. ( 31100122 )
2019
22
Effects of Age Discrimination on Self-perceptions of Aging and Cancer Risk Behaviors. ( 31100138 )
2019
23
Attitude Toward Own Aging Among Older Adults: Implications for Cancer Prevention. ( 31100140 )
2019
24
Klotho gene variant moderates the relationship between stress and epigenetic aging. ( 31100370 )
2019
25
Biomarkers of cadmium, lead and mercury exposure in relation with early biomarkers of renal dysfunction and diabetes: Results from a pilot study among aging Canadians. ( 31100493 )
2019
26
Racial differences in inflammation and outcomes of aging among kidney transplant candidates. ( 31101015 )
2019
27
Chromosomal instability and pro-inflammatory response in aging. ( 31102604 )
2019
28
Preventive effect of Lactobacillus plantarum KSFY02 isolated from naturally fermented yogurt from Xinjiang, China, on d-galactose-induced oxidative aging in mice. ( 31103296 )
2019
29
Associations between modifiable risk factors and white matter of the aging brain: insights from diffusion tensor imaging studies. ( 31103633 )
2019
30
Individual slow-wave morphology is a marker of aging. ( 31103634 )
2019
31
Dermocosmetic emulgels for anti-aging effects: Evidence from chromatographic and non-invasive biophysical techniques. ( 31103981 )
2019
32
Current Status of Healthy Aging and Dementia Research: A Symposium Summary. ( 31104030 )
2019
33
The effect of aging methods on the fracture toughness and physical stability of an oxirane/acrylate, ormocer, and Bis-GMA-based resin composites. ( 31104114 )
2019
34
Altered biogenesis of microRNA-1 is associated with cardiac dysfunction in aging of spontaneously hypertensive rats. ( 31104265 )
2019
35
Self-healing adhesive with antibacterial activity in water-aging for 12 months. ( 31104922 )
2019
36
Exploration of age-related mitochondrial dysfunction and the anti-aging effects of resveratrol in zebrafish retina. ( 31105084 )
2019
37
Gi/o-Protein Coupled Receptors in the Aging Brain. ( 31105551 )
2019
38
Aging attenuates the association between coronary artery calcification and bone loss among HIV-infected persons. ( 31107297 )
2019
39
Moxibustion improves ovary function by suppressing apoptosis events and upregulating antioxidant defenses in natural aging ovary. ( 31108096 )
2019
40
Pulse Duration and Wavelength Effects of Laser Ablation on the Oxidation, Hydrolysis, and Aging of Aluminum Nanoparticles in Water. ( 31109104 )
2019
41
Sleep and Self-Rated Health in an Aging Workforce. ( 31109268 )
2019
42
Aging: Overview and Considerations for the Development of Geriatric Foods. ( 31109282 )
2019
43
Correction to: The AGING Initiative experience: a call for sustained support for team science networks. ( 31109322 )
2019
44
Genetic and epigenetic regulation of human aging and longevity. ( 31109447 )
2019
45
Roles of long noncoding RNAs in aging and aging complications. ( 31109449 )
2019
46
Endothelial cell senescence in aging-related vascular dysfunction. ( 31109450 )
2019
47
Double knockout of Akt2 and AMPK predisposes cardiac aging without affecting lifespan: Role of autophagy and mitophagy. ( 31109453 )
2019
48
Obesity is a common soil for premature cardiac aging and heart diseases - Role of autophagy. ( 31109454 )
2019
49
Visual impairment and the use of formal and informal home care in Canada: the Canadian Longitudinal Study on Aging. ( 31109478 )
2019
50
Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation. ( 31109796 )
2019
Sources

Variations for Aging

About this section
Sources

Expression for Aging

About this section
Search GEO for disease gene expression data for Aging.
Sources

Pathways for Aging

About this section

Pathways related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 67
Show member pathways
 13.6 AKT1 JUN MAPK1 PPARG SNCA SOD1
2
Cellular Senescence (REACTOME) 67
Show member pathways
 13.18 HIF1A JUN MAPK1 SOD1 SOD2 TP53
3
TNFR1 Pathway 65
Show member pathways
 12.99 AKT1 JUN LMNA MAPK1 PARP1 TP53
4
Endometrial cancer 38
Show member pathways
 12.89 AKT1 JUN MAPK1 PDGFRB PPARG TP53
5
MAPK signaling pathway 1 38
12.8 AKT1 JUN MAPK1 PDGFRB TP53
6
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.76 AKT1 KL MAPK1 PDGFRB TP53
7
Pathways in cancer 38
12.76 AKT1 HIF1A JUN MAPK1 PDGFRB PPARG
8
Glioma 38
Show member pathways
 12.73 AKT1 JUN MAPK1 PDGFRB TP53
9
Apoptosis Modulation and Signaling 1
Show member pathways
 12.68 AKT1 JUN LMNA MAPK1 PARP1 TP53
10
4-1BB Pathway 65
Show member pathways
 12.67 AKT1 JUN MAPK1 PDGFRB SIRT3 TP53
11
ErbB signaling pathway 1 38
Show member pathways
 12.62 AKT1 HIF1A JUN MAPK1 TP53
12
Glucose / Energy Metabolism 4
12.57 AKT1 NAMPT PPARG SIRT3 SOD2
13
Apoptosis Pathway 73
Show member pathways
 12.48 AKT1 JUN PDGFRB TP53
14
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.47 AKT1 MAPK1 PPARG TP53
15
WNT Signaling 65
12.46 AKT1 JUN MAPK1 TP53
16
Phospholipase D signaling pathway 38
Show member pathways
 12.43 AKT1 HIF1A JUN MAPK1 PDGFRB
17
Human T-cell leukemia virus 1 infection 38
12.39 AKT1 JUN PDGFRB TP53
18
Selenium Micronutrient Network 1
Show member pathways
 12.36 SERPINE1 SOD1 SOD2 TP53
19
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.35 AKT1 MAPK1 PDGFRB PPARG
20
Toll Comparative Pathway 65
Show member pathways
 12.34 AKT1 JUN MAPK1 TP53
21
Proteoglycans in cancer 38
12.32 AKT1 HIF1A MAPK1 TP53
22
Apoptosis and survival Caspase cascade 23
Show member pathways
 12.3 AKT1 JUN LMNA PARP1
24
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.23 AKT1 LMNA MAPK1 PDGFRB TP53
25
Cellular senescence (KEGG) 38
12.21 AKT1 MAPK1 SERPINE1 TP53
26
mTOR Pathway 73
Show member pathways
 12.21 AKT1 JUN PPARG TP53
27
p53 Signaling 65
Show member pathways
 12.21 AKT1 HIF1A MAPK1 SIRT3 TP53
28
Integrated Breast Cancer Pathway 1
12.18 AKT1 JUN MAPK1 TP53
29
NGF Pathway 65
Show member pathways
 12.18 AKT1 JUN MAPK1 TP53
30
AKT Signaling Pathway 68
12.17 AKT1 LMNA PDGFRB TP53
31
Development EGFR signaling via small GTPases 23
Show member pathways
 12.17 AKT1 JUN MAPK1 PDGFRB
32
TGF-beta Signaling Pathway (WikiPathways) 1
12.11 AKT1 JUN MAPK1 TP53
33
Direct p53 effectors 1
12.1 JUN SERPINE1 TP53 TP63
34
Osteoclast differentiation 38
12.08 AKT1 JUN MAPK1 PPARG
35
Thyroid hormone signaling pathway 38
12.03 AKT1 HIF1A MAPK1 TP53
36
S1P3 pathway 1
Show member pathways
 12.02 AKT1 JUN MAPK1 PDGFRB
37
Glioblastoma Multiforme 65
12 AKT1 MAPK1 PDGFRB TP53
38
Senescence and Autophagy in Cancer 1
11.97 JUN MAPK1 SERPINE1 TP53
39
UVA-Induced MAPK Signaling 65
Show member pathways
 11.97 AKT1 JUN MAPK1 PARP1 TP53
40
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 11.96 AKT1 HIF1A JUN MAPK1 PPARG SERPINE1
41
HIF-1 signaling pathway 38
11.93 AKT1 HIF1A MAPK1 SERPINE1
42
AGE-RAGE signaling pathway in diabetic complications 38
11.93 AKT1 JUN MAPK1 SERPINE1
43
Adipogenesis 1
11.92 HIF1A LMNA NAMPT PPARG SERPINE1
44
Longevity regulating pathway 38
Show member pathways
 11.91 AKT1 KL PPARG SOD1 SOD2 TP53
45
Corticotropin-releasing hormone signaling pathway 1
11.9 AKT1 MAPK1 PARP1
46
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.9 AKT1 HIF1A MAPK1
47
TGF-beta Signaling Pathways 66
11.9 AKT1 JUN MAPK1 PPARG
48
TP53 Regulates Metabolic Genes 67
11.85 AKT1 TP53 TP63
49
LT-BetaR Pathway 65
Show member pathways
 11.84 AKT1 JUN MAPK1
50
DNA Damage Response (only ATM dependent) 1
11.83 AKT1 JUN MAPK1 SOD2 TP53
Sources

GO Terms for Aging

About this section

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 AKT1 HIF1A JUN LMNA MAPK1 PARP1
2 mitochondrial matrix GO:0005759 9.65 SIRT3 SNCA SOD1 SOD2 TP53
3 mitochondrion GO:0005739 9.61 AKT1 MAPK1 PARP1 SIRT3 SNCA SOD1
4 protein-containing complex GO:0032991 9.28 AKT1 HIF1A MAPK1 PARP1 PPARG SIRT3
5 nucleus GO:0005634 10.17 AKT1 HIF1A JUN LMNA MAPK1 NAMPT

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.99 AKT1 TP53 TP63 WRN
2 negative regulation of apoptotic process GO:0043066 9.98 AKT1 HIF1A JUN PDGFRB SNCA SOD1
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 HIF1A JUN NAMPT PARP1 PPARG
4 cellular response to insulin stimulus GO:0032869 9.87 AKT1 PARP1 PPARG
5 response to organic cyclic compound GO:0014070 9.86 JUN NAMPT PDGFRB PPARG
6 circadian rhythm GO:0007623 9.85 JUN NAMPT SERPINE1
7 insulin receptor signaling pathway GO:0008286 9.85 AKT1 KL NAMPT
8 regulation of signal transduction by p53 class mediator GO:1901796 9.84 AKT1 TP53 TP63
9 cellular response to hypoxia GO:0071456 9.84 AKT1 HIF1A LMNA TP53
10 protein homotetramerization GO:0051289 9.83 SOD2 TP53 TP63
11 positive regulation of endothelial cell proliferation GO:0001938 9.82 AKT1 HIF1A JUN
12 response to estrogen GO:0043627 9.81 MAPK1 PDGFRB PPARG
13 response to organic substance GO:0010033 9.81 AKT1 JUN PPARG SOD1
14 cellular response to oxidative stress GO:0034599 9.8 PARP1 SNCA SOD1 SOD2
15 regulation of blood pressure GO:0008217 9.79 PPARG SOD1 SOD2
16 response to hydrogen peroxide GO:0042542 9.77 JUN PDGFRB SOD1
17 negative regulation of neuron apoptotic process GO:0043524 9.77 HIF1A JUN SNCA SOD1 SOD2
18 cellular response to reactive oxygen species GO:0034614 9.72 AKT1 JUN MAPK1
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 AKT1 JUN NAMPT PDGFRB
20 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.7 HIF1A JUN TP53
21 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.68 AKT1 SOD2
22 removal of superoxide radicals GO:0019430 9.68 SOD1 SOD2
23 replicative senescence GO:0090399 9.68 SERPINE1 TP53
24 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.67 PPARG SOD2
25 negative regulation of telomerase activity GO:0051974 9.67 PPARG TP53
26 microglial cell activation GO:0001774 9.65 JUN NAMPT SNCA
27 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.64 AKT1 MAPK1
28 response to fluid shear stress GO:0034405 9.64 AKT1 PDGFRB
29 retina vasculature development in camera-type eye GO:0061298 9.62 HIF1A PDGFRB
30 oxygen homeostasis GO:0032364 9.61 HIF1A SOD2
31 peripheral nervous system myelin maintenance GO:0032287 9.6 AKT1 SOD1
32 response to superoxide GO:0000303 9.58 SOD1 SOD2
33 replicative cell aging GO:0001302 9.57 TP63 WRN
34 cellular response to cadmium ion GO:0071276 9.56 AKT1 JUN MAPK1 SOD1
35 positive regulation of apoptotic process GO:0043065 9.5 AKT1 JUN PDGFRB PPARG SNCA SOD1
36 cell aging GO:0007569 9.46 SOD1 TP53 TP63 WRN
37 aging GO:0007568 9.32 AKT1 JUN KL NAMPT PDGFRB SIRT3
38 negative regulation of transcription by RNA polymerase II GO:0000122 10.13 JUN PARP1 PPARG SNCA TP53 TP63
39 cellular response to DNA damage stimulus GO:0006974 10.06 AKT1 MAPK1 PARP1 TP53 WRN
40 apoptotic process GO:0006915 10.06 AKT1 MAPK1 PARP1 SNCA TP53 TP63
41 negative regulation of cell proliferation GO:0008285 10.03 JUN LMNA PPARG SOD2 TP53
42 positive regulation of gene expression GO:0010628 10.01 AKT1 HIF1A LMNA MAPK1 TP53
43 positive regulation of transcription, DNA-templated GO:0045893 10 AKT1 HIF1A JUN MAPK1 PPARG TP53

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.97 PARP1 PPARG SIRT3 SNCA SOD1 TP53
2 chromatin binding GO:0003682 9.85 JUN PPARG TP53 TP63 WRN
3 protein kinase binding GO:0019901 9.8 AKT1 HIF1A MAPK1 PARP1 PDGFRB TP53
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.71 HIF1A JUN PARP1 TP53
5 identical protein binding GO:0042802 9.7 AKT1 JUN MAPK1 NAMPT PARP1 PPARG
6 p53 binding GO:0002039 9.65 HIF1A TP53 TP63
7 transcription regulatory region DNA binding GO:0044212 9.65 JUN PPARG SNCA TP53 TP63
8 transcription factor binding GO:0008134 9.63 HIF1A JUN MAPK1 PARP1 PPARG TP53
9 copper ion binding GO:0005507 9.61 SNCA SOD1 TP53
10 superoxide dismutase activity GO:0004784 9.37